Area of research
Internal Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research focused on Warfarin and CYP2C9, with related work in Atrial fibrillation, Pharmacogenetics, Intensive care medicine. Notable publications include 'Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention', 'Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study', and 'Pharmacology of anticoagulants used in the treatment of venous thromboembolism'.
Socioecologic Factors and Racial Differences in Breast Cancer Multigene Prognostic Scores in US Women
Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT)
Implementation of pharmacogenomics into inpatient general medicine
Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Adults in the United States, 2011–2016
Why African Americans Say “No”: A Study of Pharmacogenomic Research Participation
Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six‐year population‐based cohort analysis
Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross‐sectional analysis of the National Health and Nutrition Examination Survey
Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations
Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High‐Grade Gliomas: A Nested Case‐Control Study
The <scp>ACCO</scp>u<scp>NT</scp> Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans
Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6‐year population‐based cohort study
A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Real‐World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation
Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner‐City Population
High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy
Pharmacology of anticoagulants used in the treatment of venous thromboembolism
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges
Implementation of inpatient models of pharmacogenetics programs
Anticoagulation Endpoints With Clinical Implementation of Warfarin Pharmacogenetic Dosing in a Real‐World Setting: A Proposal for a New Pharmacogenetic Dosing Approach
Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms
Practical Management of Anticoagulation in Patients With Atrial Fibrillation
Factors Influencing Pharmacokinetics of Warfarin in African–Americans: Implications for Pharmacogenetic Dosing Algorithms
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans
Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy
Evaluation of Dabigatran Bleeding Adverse Reaction Reports in the <scp>FDA</scp> Adverse Event Reporting System during the First Year of Approval
Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question
Incidence of hospital readmission in patients diagnosed with<scp>DVT</scp>and<scp>PE</scp>: clinical burden of recurrent events